QRG Capital Management Inc. increased its stake in Haemonetics Co. (NYSE:HAE – Free Report) by 6.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,031 shares of the medical instruments supplier’s stock after purchasing an additional 260 shares during the period. QRG Capital Management Inc.’s holdings in Haemonetics were worth $333,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HAE. TFO Wealth Partners LLC lifted its holdings in Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares during the period. Covestor Ltd lifted its position in Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 438 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Haemonetics during the 1st quarter valued at $86,000. Parkside Financial Bank & Trust raised its stake in shares of Haemonetics by 17.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after buying an additional 156 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Haemonetics in the first quarter valued at $114,000. Institutional investors and hedge funds own 99.67% of the company’s stock.
Insiders Place Their Bets
In other news, insider Stewart W. Strong sold 733 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $96.04, for a total transaction of $70,397.32. Following the sale, the insider now owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, EVP Josep Llorens sold 822 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $94.82, for a total transaction of $77,942.04. Following the completion of the transaction, the executive vice president now directly owns 16,350 shares in the company, valued at approximately $1,550,307. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Stewart W. Strong sold 733 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total value of $70,397.32. Following the transaction, the insider now directly owns 15,608 shares of the company’s stock, valued at $1,498,992.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,523 shares of company stock worth $2,812,120. Corporate insiders own 1.80% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have issued reports on HAE shares. Barrington Research lifted their price target on shares of Haemonetics from $107.00 to $108.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday. Finally, Needham & Company LLC upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a research report on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Haemonetics currently has an average rating of “Moderate Buy” and an average price target of $109.75.
Check Out Our Latest Stock Analysis on HAE
Haemonetics Trading Down 0.5 %
Shares of HAE opened at $74.27 on Wednesday. The stock has a 50 day simple moving average of $86.02 and a 200-day simple moving average of $84.06. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. Haemonetics Co. has a 1 year low of $70.74 and a 1 year high of $97.97. The stock has a market cap of $3.78 billion, a PE ratio of 32.43, a PEG ratio of 1.64 and a beta of 0.29.
Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $1.03 by ($0.01). The company had revenue of $336.17 million during the quarter, compared to analyst estimates of $335.08 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.05 EPS. On average, sell-side analysts predict that Haemonetics Co. will post 4.57 EPS for the current fiscal year.
Haemonetics Profile
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Featured Articles
Receive News & Ratings for Haemonetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Haemonetics and related companies with MarketBeat.com’s FREE daily email newsletter.
